Third-quarter revenue of KRW 18.6 billion and operating profit of KRW 3 billion... Operating margin at 16%
DM Power revenue more than tripled... Operating profit of KRW 1.2 billion, turning profitable

CG MedTech, a medical device company, said on Nov. 16 that its consolidated revenue and operating profit both increased in the third quarter of this year, driven by growth in its core business and improved results at its subsidiaries.


CG MedTech's consolidated revenue in the third quarter was KRW 18.6 billion, and operating profit was KRW 3 billion, up 64% and 204%, respectively, from the same period a year earlier. Its operating margin rose to 16%, up 7 percentage points from 9% in the same period last year.


A view of Sijimedtech's headquarters. Sijimedtech

A view of Sijimedtech's headquarters. Sijimedtech

View original image

Cumulative revenue from January through September was KRW 46.9 billion, up 31% from the same period last year. Cumulative operating profit rose 3% to KRW 3.6 billion. Cumulative revenue was equivalent to 99% of last year's record annual revenue of KRW 47.2 billion, raising expectations that the company will set a new annual revenue record this year.


Growth continued on a non-consolidated basis as well. CG MedTech's cumulative revenue from January through September was KRW 26.1 billion, up 26% from the same period last year. Overseas revenue increased 23% to KRW 12.1 billion. Expanded supply of implant prosthetic products and growth in its spine and orthopedic medical device businesses supported its performance.


Improved results at subsidiary DM Power also contributed to the increase in consolidated results. DM Power's third-quarter revenue was KRW 6.8 billion, more than three times the KRW 2.2 billion recorded in the same period last year. It posted an operating profit of KRW 1.2 billion, turning profitable.


From January through September, its cumulative revenue reached KRW 14.1 billion and operating profit reached KRW 1.9 billion, surpassing its full-year results last year of KRW 12.2 billion in revenue and KRW 900 million in operating profit. The results reflect sales from orders secured for Korea Electric Power Corporation's next-generation electricity meter project, AMIGO.


All Abutment, a dental-related subsidiary, also improved its profitability, with its third-quarter operating profit increasing from the same period last year.



Yoo Hyunseung, CEO of CG MedTech, said, "These results were achieved through growth in our core business and improved performance at key subsidiaries. We expect new businesses, including ECM skin boosters, to begin making a meaningful contribution to revenue starting in the fourth quarter." He added, "We will accelerate the expansion of new revenue based on our ADM CDMO supply agreement with Kolon Pharmaceutical and our collaboration with Liv Science on the ECM business."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing